NASDAQ:MSONMisonix Stock Price, Forecast & News

Misonix's stock was trading at $10.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MSON stock has increased by 31.1% and is now trading at $14.00.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Misonix in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Misonix.

Misonix is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020.
View our earnings forecast for Misonix.

Misonix will be holding an earnings conference call on Thursday, September 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Misonix, Inc. (NASDAQ:MSON) posted its quarterly earnings data on Monday, May, 11th. The medical equipment provider reported ($0.34) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.04. The medical equipment provider had revenue of $17.90 million for the quarter. Misonix had a negative return on equity of 9.13% and a negative net margin of 19.18%.
View Misonix's earnings history.

Misonix updated its fourth quarter 2020 Pre-Market earnings guidance on Friday, July, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $13.5-13.5 million, compared to the consensus revenue estimate of $8.11 million.

3 equities research analysts have issued 1-year target prices for Misonix's stock. Their forecasts range from $18.00 to $23.00. On average, they anticipate Misonix's share price to reach $21.00 in the next year. This suggests a possible upside of 50.0% from the stock's current price.
View analysts' price targets for Misonix.

News headlines about MSON stock have been trending somewhat positive recently, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Misonix earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Misonix.

Misonix saw a increase in short interest in February. As of February 15th, there was short interest totaling 510,700 shares, an increase of 18.8% from the January 31st total of 430,000 shares. Based on an average daily volume of 89,000 shares, the days-to-cover ratio is presently 5.7 days.
View Misonix's Short Interest.

Some companies that are related to Misonix include ATN International (ATNI), ChipMOS Technologies (IMOS), Team17 Group (TM17), Gree,Inc. (GREZF), Domo (DOMO), QAD (QADA), Axcelis Technologies (ACLS), Ceres Power (CWR), Upland Software (UPLD), XP Power (XPP), Eventbrite (EB), Criteo (CRTO), FIH MOBILE LTD/ADR (FXCNY), the Rubicon Project (MGNI) and Oxford Instruments (OXIG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Misonix investors own include Edap Tms (EDAP), Canopy Growth (CGC), Varian Medical Systems (VAR), Second Sight Medical Products (EYES), Sociedad Quimica y Minera de Chile (SQM), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), Ardelyx (ARDX), Athenex (ATNX) and Main Street Capital (MAIN).

Misonix trades on the NASDAQ under the ticker symbol "MSON."

Misonix's stock is owned by many different retail and institutional investors. Top institutional investors include Acuitas Investments LLC (1.02%), Mesirow Financial Investment Management Inc. (0.13%), New York State Common Retirement Fund (0.09%), Ingalls & Snyder LLC (0.07%) and SG Americas Securities LLC (0.05%). Company insiders that own Misonix stock include Christopher H Wright, Joseph J Brennan, Joseph P Dwyer, Sharon W Klugewicz and Stavros G Vizirgianakis.
View institutional ownership trends for Misonix.

MSON stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC.
View insider buying and selling activity for Misonix.

MSON stock was acquired by a variety of institutional investors in the last quarter, including Acuitas Investments LLC, New York State Common Retirement Fund, SG Americas Securities LLC, and Mesirow Financial Investment Management Inc.. Company insiders that have bought Misonix stock in the last two years include Joseph P Dwyer, Sharon W Klugewicz, and Stavros G Vizirgianakis.
View insider buying and selling activity for Misonix.

Shares of MSON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MSON stock can currently be purchased for approximately $14.00.

Misonix has a market capitalization of $243.07 million and generates $38.85 million in revenue each year. Misonix employs 118 workers across the globe.

The official website for Misonix is www.misonix.com.

Misonix's mailing address is 1938 NEW HIGHWAY, FARMINGDALE NY, 11735. The medical equipment provider can be reached via phone at 631-694-9555.